菜单

Services & Solutions
Information Downloads

Developing a Stable Formula at 180 mg/mL
WuXiHigh™ 2.0 Enables Subcutaneous Self-Administration

High-concentration biologics are the gateway to low-volume dosing and subcutaneous self-administration. For a pharmaceutical client developing a monoclonal antibody to treat chronic disease, pivoting from intravenous delivery to subcutaneous was key to success.

 

Additional program requirements—viscosity below 20 cP and an ultra-tight 2-month timeline—called for WuXi Biologic’s advanced expertise and WuXiHigh 2.0, an exclusive technology platform. The platform accelerated screening and optimization to quickly reach a 180 mg/mL concentration, ensuring both stability and manufacturability.

 

The resulting formulation supported subcutaneous delivery via a 5 mL prefilled syringe, meeting all targets within the defined schedule. Read the case study to see how WuXiHigh 2.0 advanced subcutaneous delivery with speed, precision, and confidence.

Discuss This Case Study

To discuss the information in this case study, please complete the form on the following page to connect with our experts.

Connect with our Experts